drugset / Trial / NCT00821912
TaxXel: Taxotere and Xeloda in Esophageal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, non-randomised, multicentre phase 1-2 study with a fixed dose of Taxotere in combination with Xeloda which is dose escalated during the first phase of the study (modified Fibonacci design) and fixed during the second phase. The primary objective of the phase 1 part is to define the dose recommended for the Phase II part of the study. The primary objective is to determine the response rate.
Timeline
- Start
- 2006-03
- Primary completion
- 2012-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1650 mg/m2 | Oral |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |